harpagoside (Compound)

Synonyms:Harpagoside, 19210-12-9, E-harpagoside, 8KGS1DC5ZU, CHEBI:5625, [(1S,4aS,5R,7S,7aS)-4a,5-dihydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-7-yl] (E)-3-phenylprop-2-enoate, SMR001233395, UNII-8KGS1DC5ZU, Harpaside, EINECS 242-881-6, Prestwick3_000988, HARPAGOSIDE [INCI], BSPBio_001055, HARPAGOSIDE [WHO-DD], MLS002154086, MLS002473324, SCHEMBL893387, BPBio1_001161, CHEMBL516702, MEGxp0_000469, Harpagoside, analytical standard, ACon0_000056, ACon1_000134, DTXSID101032528, HMS2098E17, HMS2231N12, HY-N0396, MFCD00017415, s9171, AKOS015896715, CCG-269650, LMPR0102070010, NCGC00179325-01, NCGC00179325-02, NCGC00179325-04, AC-34268, AS-56071, AB00513986, CS-0008931, C09783, H10494, EN300-7357122, A880338, Q-100231, BRD-K07996107-001-01-7, BRD-K07996107-001-03-3, Harpagoside, primary pharmaceutical reference standard, Q25099323, Harpagoside, European Pharmacopoeia (EP) Reference Standard, (1S,4aS,5R,7S,7aS)-4a,5-Dihydroxy-7-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-7-yl cinnamate, (1S,4aS,5R,7S,7aS)-4a,5-dihydroxy-7-methyl-1-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-7-yl cinnamate, (1S,4aS,5R,7S,7aS)-4a,5-dihydroxy-7-methyl-1-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1H,4aH,5H,6H,7H,7aH-cyclopenta[c]pyran-7-yl (2E)-3-phenylprop-2-enoate, (1S-(1alpha,4aalpha,5alpha,7alpha(E),7aalpha))-1,4a,5,6,7,7a-Hexahydro-4a,5-dihydroxy-7-methyl-7-((allyl-1-oxo-3-phenyl)oxy)cyclopenta(c)pyran-1-yl-beta-D-glucopyranoside, .BETA.-D-GLUCOPYRANOSIDE, (1S,4AS,5R,7S,7AS)-1,4A,5,6,7,7A-HEXAHYDRO-4A,5-DIHYDROXY-7-METHYL-7-(((2E)-1-OXO-3-PHENYL-2-PROPENYL)OXY)CYCLOPENTA(C)PYRAN-1-YL

Pubchem:PUBCHEM:5281542

Id:4b3665c5-8da5-50cf-8ae6-04e87dac53ba

Description:nan